Research theme for competitive and other funds (7):
2021 - 2024 NAD代謝による組織因子制御と慢性腎臓病血栓症の予防法開発
2021 - 鈴木万平糖尿病財団 海外留学助成
2018 - 2021 プロテアーゼ活性化受容体2によるオートファジー制御と慢性腎臓病合併心血管病
2016 - 2019 妊娠高血圧腎症における凝固因子及びプロテアーゼ活性化受容体の役割
2016 - 全身性エリテマトーデス合併妊娠の病態解明と新規治療法の開発
2016 - 腎性貧血、腎性骨症におけるプロテアーゼ活性化受容体2 (PAR2) の役割
2013 - IgA腎症に対するニコチン酸アミドの効果
Show all
Papers (52):
Takehiko Wada, Sayaka Shimizu, Masahiro Koizumi, Tadashi Sofue, Hiroki Nishiwaki, Sho Sasaki, Izaya Nakaya, Yuji Oe, Takuji Ishimoto, Kengo Furuichi, et al. Japanese clinical practice patterns of primary nephrotic syndrome 2021: a web-based questionnaire survey of certified nephrologists. Clinical and experimental nephrology. 2023
Shizuka Ishigaki, Yuji Oe, Kei Omata, Yoshikiyo Ono, Yuta Tezuka, Ryo Morimoto, Shun Watanabe, Hiroyasu Nishioka, Fumitoshi Satoh, Mai Yoshida, et al. Marked reduction of proteinuria after removal of a growth hormone-producing pituitary adenoma in a patient with focal segmental glomerulosclerosis: a case report and literature review. CEN case reports. 2022
Aleix Navarro Garrido, Young Chul Kim, Yuji Oe, Haiyan Zhang, Maria Crespo-Masip, Helen A. Goodluck, Sadhana Kanoo, Paul W. Sanders, Stefan Bröer, Volker Vallon. Aristolochic acid-induced nephropathy is attenuated in mice lacking the neutral amino acid transporter B0AT1 (Slc6a19). American Journal of Physiology-Renal Physiology. 2022. 323. 4. F455-F467
Yuji Oe, Volker Vallon. The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1. Kidney and Dialysis. 2022. 2. 2. 349-368
Yuki Chiba, Kei Takahashi, Rui Makino, Mai Yoshida, Yuji Oe, Tasuku Nagasawa, Hiroshi Sato, Mariko Miyazaki, Koji Okamoto. Glomerulonephritis Associated with Infective Endocarditis Showing Serological Positivity for PR3-anti-neutrophil Cytoplasmic Antibody and Anti-glomerular Basement Membrane Antibody. Internal medicine (Tokyo, Japan). 2021. 61. 14. 2179-2185